Cipla vs Apollo Hospitals Enterprise Q3 FY26

Cipla's Q3 FY26 revenue was flat YoY at INR 7,074 crore, with EBITDA margin of 17.7% (down ~150-200bps vs internal expectations) due to lower generic revenues and elevated R&D spend (7% of sales, +37% YoY). PAT of INR 676 crore included a one-time INR 276 crore labor code charge. U.S. revenue fell to $167 million as Lenalidomide tapered and lanreotide supply was disrupted (partner Pharmathen paused production after FDA observations; resupply expected H1 FY27). India business grew 10% YoY, with respiratory crossing INR 5,000 crore. FY26 EBITDA margin guidance revised to ~21%. Key upcoming U.S. launches (4 respiratory, 4 peptide assets) are expected to offset revenue declines, but near-term headwinds persist. Risk: lanreotide disruption may extend beyond H1 FY27 if remediation is delayed.

Guidance read

FY26 EBITDA margin guidance revised to ~21%: Management lowered FY26 EBITDA margin guidance to ~21% from earlier expectations, citing lower lanreotide and Lenalidomide impact. U.S. launches: 4 respiratory and 4 peptide assets in FY27: Pipeline includes generic Advair, two other large respiratory assets (likely Symbicort), and three peptide launches including generic Victoza. Lanreotide resupply expected in H1 FY27: Partner Pharmathen paused production; resupply expected in H1 FY27, with alternate site evaluation underway. FY27 guidance to be provided next quarter: Management will provide FY27 guidance after finalizing the annual operating plan.

Risk read

Key risks include Lanreotide supply disruption may extend beyond H1 FY27 — Pharmathen's manufacturing pause and 483 observations could delay resupply, impacting U.S. revenue.; U.S. launch pipeline may face delays or competition — Respiratory and peptide launches are critical to offset Lenalidomide decline; any delay or increased competition could pressure revenue.; Elevated R&D spend may persist, pressuring margins — R&D at 7% of revenue is above historical 5-6% range; management expects normalization but lumpy spending could continue.; Semaglutide generic launch could impact tirzepatide uptake — Analyst questioned whether Cipla's agreement with Lilly restricts entry into semaglutide; management was evasive..

Promise ledger

Of 1 tracked promise, management 0 met, 0 close, 1 missed.

Apollo Hospitals delivered a strong Q3 FY26 with consolidated revenue of INR 6,477 crore (+17% YoY) and PAT of INR 502 crore (+35% YoY), driven by double-digit growth across all verticals. Healthcare services revenue grew 14% to INR 3,183 crore, supported by 5% volume growth, 5% pricing, and 4% case mix improvement. Apollo Healthco revenue rose 20% to INR 2,827 crore, with digital losses narrowing to INR 67 crore. AHLL EBITDA grew 39% to INR 48 crore. Management guided for INR 150 crore in new hospital startup costs next year, partially offset by 100 bps margin expansion in existing hospitals. The digital business cash EBITDA breakeven is delayed by one quarter to Q1 FY27 due to insurance revenue recognition changes. Risk: new bed ramp-up may pressure near-term margins if occupancy lags.

Guidance read

New bed additions of ~1,500 over next two years: Approximately 1,500 new beds will be added across four new hospitals, with ~50% operationalized in FY27 and balance in early FY28. Startup losses of INR 150 crore in FY27: Management expects total startup losses of INR 150 crore from new hospitals in FY27, with potential quarterly peaks of INR 50 crore. Digital business cash EBITDA breakeven delayed to Q1 FY27: Cash EBITDA breakeven for Apollo 24/7 pushed out by one quarter to Q1 FY27 due to insurance revenue recognition changes. Existing hospital margin expansion of 100 bps in FY27: Management expects 100 bps margin improvement in existing hospitals next year through asset utilization and cost optimization.

Risk read

Key risks include New hospital ramp-up delays and cost overruns — Gurugram hospital delayed by 2-3 months due to environmental clearance issues; startup losses could exceed INR 150 crore if occupancy ramps slower than expected.; Insurance contract renegotiation delays — Some insurance contract renewals have been pushed out, potentially impacting revenue mix and ARPP growth in certain markets.; Digital business revenue recognition changes — Changes in GST and insurance commission recognition caused a INR 7 crore revenue deferral in Q3, delaying cash EBITDA breakeven by one quarter.; Talent poaching risk in competitive market — Recent poaching of a star oncologist by a peer highlights retention risk, though management believes Apollo's brand and platform mitigate this..

Promise ledger

Of 3 tracked promises, management 0 met, 0 close, 3 missed.